Walvax Biotechnology Co

Walvax Biotechnology Co EBIT

The EBIT of Walvax Biotechnology Co (300142.SZ) as of Oct 29, 2026 is 69.96 M CNY. In the previous year, EBIT was 96.67 M CNY — a change of -27.63% (lower).

EBIT

69.96 MCNY

YoY

-27.63%

Last updated:

In 2025, Walvax Biotechnology Co's EBIT was 69.96 M CNY, a -27.63% increase from the 96.67 M CNY EBIT recorded in the previous year.

The Walvax Biotechnology Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
710.28 M CNY
Jan 1, 2022
1.10 B CNY
Jan 1, 2023
613.97 M CNY
Jan 1, 2024
96.67 M CNY
Jan 1, 2025
69.96 M CNY
Jan 1, 2026 (e)
68.08 M CNY
Jan 1, 2027 (e)
195.87 M CNY
Jan 1, 2028 (e)
259.76 M CNY
The Walvax Biotechnology Co EBIT history
YEAREBITYoY
est259.76 MCNY+32.62%
est195.87 MCNY+187.70%
est68.08 MCNY-2.69%
69.96 MCNY-27.63%
96.67 MCNY-84.25%
613.97 MCNY-44.16%
1.10 BCNY+54.79%
710.28 MCNY-48.39%
1.38 BCNY+490.97%
232.88 MCNY+76.79%
131.73 MCNY-241.63%
-93.01 MCNY-159.85%
155.39 MCNY-117.30%
-898.16 MCNY-800.81%
128.16 MCNY+3,552.91%
3.51 MCNY-98.42%
222.69 MCNY+12.63%
197.71 MCNY+11.78%
176.88 MCNY+69.79%
104.18 MCNY+196.26%
35.16 MCNY+533.66%
5.55 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Walvax Biotechnology Co Revenue

Walvax Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
3.46 B CNY
710.28 M CNY
427.75 M CNY
Jan 1, 2022
5.09 B CNY
1.10 B CNY
728.65 M CNY
Jan 1, 2023
4.11 B CNY
613.97 M CNY
419.39 M CNY
Jan 1, 2024
2.82 B CNY
96.67 M CNY
142.16 M CNY
Jan 1, 2025
2.41 B CNY
69.96 M CNY
177.74 M CNY
Jan 1, 2026 (e)
1.88 B CNY
68.08 M CNY
48.00 M CNY
Jan 1, 2027 (e)
2.30 B CNY
195.87 M CNY
143.99 M CNY
Jan 1, 2028 (e)
2.61 B CNY
259.76 M CNY
191.98 M CNY

Walvax Biotechnology Co Margins

Walvax Biotechnology Co stock margins

The Walvax Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Walvax Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Walvax Biotechnology Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
88.35 %
20.51 %
12.35 %
Jan 1, 2022
86.77 %
21.62 %
14.33 %
Jan 1, 2023
81.78 %
14.92 %
10.19 %
Jan 1, 2024
73.76 %
3.43 %
5.04 %
Jan 1, 2025
68.85 %
2.90 %
7.37 %
Jan 1, 2026 (e)
68.85 %
3.62 %
2.55 %
Jan 1, 2027 (e)
68.85 %
8.50 %
6.25 %
Jan 1, 2028 (e)
68.85 %
9.96 %
7.36 %

Walvax Biotechnology Co Stock analysis

What does Walvax Biotechnology Co do? Walvax Biotechnology Co Ltd is a leading Chinese biotech company specializing in the research, development, production, and marketing of vaccines, antibodies, and diagnostic reagents. The company was founded in 2001 and is headquartered in Beijing. Over the past 20 years, the company has become one of the largest and most advanced biotech companies in the country, capable of offering high-quality and cost-effective products. Walvax Biotechnology is committed to promoting public health and improving people's quality of life. The business model of Walvax Biotechnology is based on the integration of research and development, production, and distribution. The company offers a wide range of products and services and works closely with government agencies and other partners to improve healthcare in China and abroad. The company has various segments, including research and development, vaccine and biological drug production, diagnostic reagent production, and the distribution of medical devices and products. The research and development sector of Walvax Biotechnology has enabled the company to develop a variety of vaccines and biological drugs that contribute to the prevention and treatment of diseases. Some of the company's key vaccines include the Hepatitis A vaccine, Hepatitis E vaccine, rabies vaccine, varicella vaccine, and polio vaccine. In addition, the company has also developed antibody products that can be used for the treatment of cancer and other diseases. Some of the company's key products include the humanized monoclonal antibody against Epidermal Growth Factor Receptor (EGFR) and the humanized monoclonal antibody against Programmed Death-1 (PD-1) receptor. Walvax Biotechnology is also a major producer of diagnostic reagents used for the identification of infections and other diseases. Some of the company's key products include the HIV-ELISA test, HCV-ELISA test, and HBsAg-ELISA test. The distribution sector of Walvax Biotechnology includes the sale of medical devices and products such as blood collection needles and infusion sets. The company has also established partnerships with other companies and organizations to promote the sales and distribution of its products on an international level. Overall, Walvax Biotechnology Co Ltd has become one of China's leading biotech companies. The company has a strong presence in the vaccine industry and has gained a reputation as an innovator and producer of high-quality products. The company is committed to continuing to grow and expand its range of products and services to make a positive contribution to public health. Walvax Biotechnology Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Walvax Biotechnology Co's EBIT

Walvax Biotechnology Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Walvax Biotechnology Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Walvax Biotechnology Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Walvax Biotechnology Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Walvax Biotechnology Co stock

EBIT of Walvax Biotechnology Co is 69.96 M CNY in 2025.

EBIT of Walvax Biotechnology Co changed from 96.67 M CNY to 69.96 M CNY, representing a -27.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Walvax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Walvax Biotechnology Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Walvax Biotechnology Co

All Key Metrics — Walvax Biotechnology Co